<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185925</url>
  </required_header>
  <id_info>
    <org_study_id>444-14</org_study_id>
    <secondary_id>14a</secondary_id>
    <nct_id>NCT01185925</nct_id>
  </id_info>
  <brief_title>Exercise Oscillatory Breathing and Sildenafil in Heart Failure</brief_title>
  <official_title>PDE5-Inhibition With Sildenafil Reverses Exercise Oscillatory Breathing in Chronic Heart Failure: a Long-Term Cardiopulmonary Exercise Testing Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <brief_summary>
    <textblock>
      Exercise oscillatory breathing (EOB) is a ventilatory abnormality that occurs in
      approximately 20% of heart failure (HF) patients and carries a very unfavourable prognosis.

      Pathophysiology seems quite complex and putative mechanisms include increased pulmonary
      capillary pressure and pulmonary vasoconstriction, circulatory blood-flow fluctuations in the
      pulmonary arterial system and instability of ventilatory control.

      Inhibition of the phosphodiesterase 5 (PDE5) isoenzyme favourably regulates pulmonary
      vascular tone and permeability through over signaling of the endothelial nitric oxide
      pathway. The investigators tested the hypothesis that sildenafil would reverse the EOB
      pattern in patients with HF and pulmonary hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Effect on Oscillatory Breathing during Exercise</measure>
    <time_frame>1 year follow-up</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sildenafil, pde5 inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment group; sildenafil 50 mg three times a day for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Sildenafil, 50 mg 3 times/day</description>
    <arm_group_label>sildenafil, pde5 inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  consent to participate in the study after detailed information about benefits and
             risks

          -  negative exercise stress test prior to study initiation

          -  forced expiratory volume in 1 sec/forced vital capacity ratio &gt;70%;

          -  LVEF &lt; 45%.

        Exclusion Criteria:

          -  inability to complete a maximal exercise test

          -  resting systolic blood pressure &gt; 140 or &lt;110 mmHg

          -  therapy with nitrate preparations

          -  history of sildenafil intolerance

          -  significant lung or valvular diseases

          -  neuromuscular disorders or peripheral vascular disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2010</study_first_posted>
  <last_update_submitted>August 4, 2011</last_update_submitted>
  <last_update_submitted_qc>August 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marco Guazzi</name_title>
    <organization>Cardiopulmonary Unit, University of Milano</organization>
  </responsible_party>
  <keyword>PDE5-inhibition</keyword>
  <keyword>exercise ventilation</keyword>
  <keyword>heart failure</keyword>
  <keyword>sildenafil</keyword>
  <keyword>pulmonary hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

